Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-World shares rise on recovery hopes after record November

Tue, 01st Dec 2020 13:47

(Adds details, updates prices, changes dateline)

* World shares up 0.4%, U.S. futures up sharply

* Vaccine hopes drives optimism after EZ factory recovery
falters

* China factory activity growth hits decade high in November

* U.S. dollar weakens, Bitcoin off record highs

* Oil volatile after OPEC+ talks delay, copper up

By Danilo Masoni

MILAN, Dec 1 (Reuters) - World shares rose to just below
record peaks on Tuesday after factory surveys boosted
expectations of a recovery from the COVID-19 downturn, with
drugmakers seeking fast approval for vaccines and authorities
looking set to maintain stimulus.

Bets on more easing from the U.S. Federal Reserve to help
the pandemic-hit economy through the winter weighed on the
dollar as riskier currencies rose, while crude prices struggled
to join the bounce after oil-producing countries delayed a
decision on output cuts.

The MSCI world equity index, which tracks
shares in 49 countries, was up 0.4% by 1323 GMT.

Breakthroughs in vaccine developments from top drugmakers
Pfizer, Moderna and AstraZeneca in
November along with a market-friendly outcome of the U.S.
presidential election helped the index score its best month on
record, up 12% to new all-time peaks.

"We believe the rally can continue, with the current
pipeline of expected vaccine rollouts in line with our central
scenario of widespread availability in the second quarter of
2021," said Mark Haefele, Chief Investment Officer at UBS Global
Wealth Management in Zurich.

"We also believe that a divided U.S. government - which
looks the most likely outcome - is no impediment to a rising
market," he added.

In Europe the pan-regional STOXX 600 benchmark was
up 0.7%, while U.S. stock index futures also pointed to a strong
start on Wall Street, with investors focusing on November
manufacturing surveys from Europe and the United States.

Euro zone factory surveys were less upbeat than China's as
growth in the region cooled last month from a 32-month high on
renewed lockdown measures. However, optimism did improve amid
progress in developing COVID-19 vaccines.

In the UK, factories recorded their fastest growth in almost
three years last month.

Earlier the MSCI's broadest index of Asia-Pacific shares
outside Japan closed up 1.3%. China's blue-chip
CSI300 index rose 2.2% after a business survey showed
activity in China's factory sector accelerated at the fastest
pace in a decade in November.

Japan's Nikkei closed near a 29-1/2-year high.

"What we are seeing today is that upward trend reasserting
itself, given the positive news on the vaccine front, China's
growth picking up, and the tremendous faith in the ability of
central banks to keep the markets afloat," said Stephen Miller,
market strategist for GSFM Funds Management.

Pfizer on Tuesday said it had asked for EU emergency
authorization of its vaccine, taking it closer to launch
following a similar move in the United States last month.

Moderna applied for U.S. authorization on Monday
after full results from a late-stage study showed it was 94.1%
effective with no serious safety concerns.

In foreign exchange markets, the dollar was under pressure
after closing out on Monday its worst month since July with a
little bounce, and as investors reckon on even more U.S.
monetary easing.

The dollar index was last down 0.2% to 91.758.

In a speech released late on Monday, Fed chair Jerome Powell
said a slowing recovery and a surging pandemic meant the U.S.
was entering a "challenging" few months, with the potential
deployment of a vaccine still facing hurdles.

The Fed holds its next policy meeting later this month.

That lifted the euro close to a three-month high,
up 0.4% at $1.1974, while risk-related currencies such as the
Canadian and Aussie dollar rose against the greenback.

Elsewhere sterling was up 0.5% after hitting a
three-month high as traders clung to hopes for a Brexit trade
deal before the year's end, despite the lack of tangible
progress.

Bitcoin was volatile, last down 6% after hitting
a record high earlier in the day.

Bond markets were quieter. Germany's 10-year bond yield
nudged off three-week lows at -0.564%, while
southern European debt yields also edged up, though they held
close to record lows ahead of next week's European Central Bank
meeting.

Data on Tuesday showing a bigger than expected drop in euro
zone inflation in November didn't move bond markets much but
cemented expectations for the ECB to take action.

"The message is clear for the ECB. As this has been the base
case for some time now, it will without a doubt make the ECB
loosen policy once again," said ING senior economist Bert Colijn
in Amsterdam.

U.S. 10-year yields were up slightly at 0.8602%
as the U.S. Congress began a two-week sprint to secure funding
and avoid a possible shutdown amid the coronavirus pandemic.

Metal markets were buoyant, reflecting the risk-on mood.
London copper prices pushed back towards Monday's 7-1/2-year
high, helped by the robust data from China.

Oil prices were volatile after leading producers delayed
talks on 2021 output policy, while the coronavirus pandemic
continued to sap fuel demand.

OPEC+ delayed talks on output policy for next year until
Thursday, sources told Reuters, as key players still disagreed
on how much oil they should pump amid weak demand.

Brent crude futures were last 0.2% lower at $47.8 a
barrel, while U.S. crude also eased 0.4% to $45.16.

(Reporting by Danilo Masoni in Milan, additional reporting by
Paulina Duran in Sydney; Editing by Mike Collett-White and Jan
Harvey)

More News
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more
1 Dec 2023 08:01

AstraZeneca calls off two phase III trials into hyperkalaemia treatment

(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.

Read more
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.